Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: A case study

Peptides

Volumn 28, Issue 9, 2007, Pages 1891-1895

  Li, Min ^a   Maderdrut, Jerome L ^a   Lertora, Juan J L ^a   Batuman, Vecihi ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Inflammation; Light chain immunoglobulins; Mitogen activated protein kinase; Myeloma kidney; PACAP; PACAP receptors

Indexed keywords

GLUCOSE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE;

AGED; ARTICLE; BLOOD GAS; BLOOD PRESSURE; CASE REPORT; CONTINUOUS INFUSION; DRUG EFFECT; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY CANCER; KIDNEY MYELOMA; LIGHT CHAIN; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED, 80 AND OVER; CYTOKINES; HUMANS; IMMUNOGLOBULIN LAMBDA-CHAINS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE; MALE; MULTIPLE MYELOMA; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; TREATMENT OUTCOME;

RATTUS;

EID: 34548453542     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.05.002     Document Type: Article

References (37)

1. Arimura A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn J Physiol 48 (1998) 301-331
2. Arimura A., Li M., and Batuman V. Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 107 (2006) 661-668
3. Arimura A., Li M., and Batuman V. Treatment of renal failure associated with multiple myeloma and other diseases by PACAP-38. Ann N Y Acad Sci 1070 (2006) 1-4
4. Delgado M., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kB-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem 276 (2001) 369-380
5. Delgado M., Martinez C., Pozo D., Calvo J.R., Leceta J., Ganea D., et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol 162 (1999) 1200-1205
6. Filipsson K., Tornoe K., Holst J., and Ahren B. Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans. J Clin Endocrinol Metab 82 (1997) 3093-3098
7. 2 terminus. J Clin Invest 78 (1986) 906-913
8. Ganea D., and Delgado M. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP. Arch Immunol Ther Exp (Warsz) 49 (2001) 101-110
9. Hammond P.J., Talbot K., Chapman R., Ghatei M.A., and Bloom S.R. Vasoactive intestinal peptide, but not pituitary adenylate cyclase-activating peptide, modulates the responsiveness of the gonadotroph to LHRH in man. J Endoccrinol 137 (1993) 529-532
10. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50 (1998) 265-270
11. Haubitz M., and Peest D. Myeloma-new approaches to combined nephrological-haematological management. Nephrol Dial Transplant 21 (2006) 582-590
12. Hideshima T., Chauhan D., Schlossman R., Richardson P., and Anderson K.C. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20 (2001) 4519-4527
13. Hideshima T., Nakamura N., Chauhan D., and Anderson K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20 (2001) 5991-6000
14. Iggo N., Winearls C.G., and Davies D.R. The development of cast nephropathy in multiple myeloma. QJM 90 (1997) 653-656
15. Kieffer T.J., McIntosh C.H., and Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (1995) 3585-3596
16. Lelievre V., Pineau N., and Waschek J.A. The biological significance of PACAP and PACAP receptors in human tumors: from cell lines to cancers. In: Vaudry H., and Arimura A. (Eds). Pituitary adenylate cyclase-activating polypeptide (2003), Kluwer Academic Publishers, Dordrecht 361-399
17. Li M., Cortez S., Nakamachi T., Batuman V., and Arimura A. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells. Cancer Res 66 (2006) 8796-8803
18. Li M., Mbikay M., and Arimura A. Pituitary adenylate cyclase-activating polypeptide precursor is processed solely by prohormone convertase 4 in the gonads. Endocrinology 141 (2000) 3723-3730
19. Li M., Mbikay M., Nakayama K., Miyata A., and Arimura A. Prohormone convertase PC4 processes the precursor of PACAP in the testis. Ann N Y Acad Sci 921 (2000) 333-339
20. Li M., Nakayama K., Shuto Y., Somogyvari-Vigh A., and Arimura A. Testis-specific prohormone convertase PC4 processes the precursor of pituitary adenylate cyclase-activating polypeptide (PACAP). Peptides 19 (1998) 259-268
21. Li M., Shuto Y., Somogyvari-Vigh A., and Arimura A. Prohormone convertases 1 and 2 process ProPACAP and generate matured, bioactive PACAP38 and PACAP27 in transfected rat pituitary GH4C1 cells. Neuroendocrinology 69 (1999) 217-226
22. Lin J., Markowitz G.S., Valeri A.M., Kambham N., Sherman W.H., Appel G.B., et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 12 (2001) 1482-1492
23. Mentlein R., Gallwitz B., and Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214 (1993) 829-835
24. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164 (1989) 567-574
25. Miyata A., Jiang L., Dahl R.D., Kitada C., Kubo M., Fujono M., et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170 (1990) 643-648
26. Ogata A., Chauhan D., Teoh G., Treon S.P., Urashima M., Schlossman R.L., et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 159 (1997) 2212-2221
27. Podar K., Tai Y.T., Davies F.E., Lentzsch S., Sattler M., Hideshima T., et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98 (2001) 428-435
28. Reubi J.C., Laderach U., Waser B., Gebbers J.O., Robberecht P., and Laissue J.A. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 60 (2000) 3105-3112
29. Ritz E. Cast nephropathy in myeloma-does PACAP38, a new member of the vasoactive intestinal peptide family, open a therapeutic window?. J Am Soc Nephrol 17 (2006) 911-913
30. Roato I., Grano M., Brunetti G., Colucci S., Mussa A., Bertetto O., et al. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J 19 (2005) 228-230
31. Roux S., and Mariette X. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression. Leuk Lymphoma 45 (2004) 1111-1118
32. Sanders P.W. A new twist in myeloma treatment. Blood 107 (2006) 413-414
33. Sati H.I., Greaves M., Apperley J.F., Russell R.G., and Croucher P.I. Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br J Haematol 104 (1999) 350-357
34. Schulz S., Rocken C., Mawrin C., Weise W., Hollt V., and Schulz S. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies. Clin Cancer Res 10 (2004) 8235-8242
35. Segre G.V., and Goldring S.R. Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-prptein-linked receptor family. Trends Endocrinol Metab 4 (1993) 309-314
36. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., and Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52 (2000) 269-324
37. Zhu L., Tamvakopoulos C., Xie D., Dragovic J., Shen X., Fenyk-Melody J.E., et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 278 (2003) 22418-22423